Fulton, MD – March 4, 2025 – SimonMed, one of the largest outpatient imaging providers in the U.S., has implemented MagView’s Luminary Risk, an advanced risk assessment software, as a core component of its Personalized Breast Cancer Detection Program. This integration streamlines high-risk assessment, ensuring patients receive the most tailored and comprehensive breast cancer screening.
Luminary Risk delivers a patient history collection platform that highlights clear, actionable risk scores, patient recommendations and care plans, helping SimonMed identify women who may need additional screening beyond a standard mammogram. Its intuitive interface and automated risk stratification optimize efficiency for both patients and staff.
“Luminary Risk is an essential component of SimonMed’s new Personalized Breast Cancer Detection Program, enabling us to seamlessly incorporate high-risk assessment into our workflow,” said Sean Raj, Chief Innovation Officer at SimonMed. “Its intuitive interface simplifies the process for both patients and staff, ensuring efficient and accurate risk stratification. By performing over a thousand risk assessments daily—including Tyrer-Cuzick scoring and comprehensive risk questionnaires—this platform allows us to identify women who may benefit from additional screening beyond a standard mammogram. MagView’s technology has been instrumental in delivering a truly personalized approach to breast cancer detection for our patients.”
SimonMed’s AI-powered detection program integrates Luminary Risk with advanced imaging technologies to enhance early detection and patient care.
“SimonMed is setting a new standard for breast cancer screening with AI-driven imaging and personalized risk assessment,” said Mark Schmidt, VP of Sales & Marketing at MagView. “We are proud to support them in identifying high-risk patients while improving workflow efficiency.”
For more information about MagView’s Luminary Risk, visit www.magview.com.
